this press release on the wire today...wonder if it will have any effect
STRESSGEN RECEIVES NOTICE OF ALLOWANCE OF
CANADIAN PATENT FOR INFECTIOUS DISEASE VACCINES
AND CANCER TREATMENTS USING STRESS PROTEINS
VICTORIA, Oct. 28 /CNW/ - StressGen Biotechnologies Corp. announced today
it has received Notice of Allowance for a Canadian patent protecting its core
technology. The patent covers the use of stress proteins in the development of
infectious disease vaccines and cancer treatments within Canada.
Richard M. Glickman, StressGen's president and chief executive officer,
said the Canadian patent is part of the company's program to obtain protection
for its technology around the world. The company received a European patent in
1995 and has patents pending in the United States.
``This patent considerably strengthens our proprietary position,''
Glickman said. ``It will provide StressGen with an important commercial
foundation upon which to build a strong domestic market for its vaccine and
cancer therapeutic products.''
StressGen's core technology capitalizes on the special ability of stress
proteins to strongly activate the human immune system to fight cancer and
infection by foreign microbes. The company expects to begin clinical trials on
the first of a series of products in 1997.
StressGen also announced the appointment of Dr. Richard Voellmy to the
position of Vice President, Intellectual Property and Planning. A noted
scientist and lawyer, Dr. Voellmy will manage the company's patent portfolio.
``Dr. Voellmy's experience managing intellectual property and his
extensive research experience will significantly enhance our ability to
identify and secure new applications that use stress proteins and stress
protein genes to treat and prevent disease,'' said Glickman.
Dr. Voellmy joins StressGen from the University of Miami School of
Medicine, Department of Chemistry & Molecular Biology where he has been a
professor since 1987. He is a co-founder of StressGen and has served on its
Scientific Advisory Board since 1990.
StressGen Biotechnologies Corporation is a biopharmaceutical company
engaged in the research and development of stress proteins for use in cancer
therapy and vaccines to prevent disease. The company is also an international
leader in the development, manufacture and sale of stress protein research
biochemicals.
Toronto Stock Exchange Symbol -- SSB
Vancouver Stock Exchange Symbol -- SSB
US Rule 12g3-2(b) Exemption No.82-3776
For further information: Investor Contact: Michelle Lurch-Shaw, StressGen
Biotechnologies, (604) 744-2811; Media Contact: Lorraine Wilson, James Hoggan &
Assoc., (604) 739-7500
07:00e 28-OCT-96 |
